作为中国医药工业体系中的"隐形巨擘"，某总部位于华东的医药集团（以下简称"该集团"或"集团"）长 期占据中国医药工业百强榜首位置，其发展历程是中国本土药企从"仿制药规模化"向"创新药差异化"转 型的经典缩影。 本报告对该集团进行了全方位的解构，核心发现包括： 1. 集团概况与历史沿革：从地方小厂到行业巨头 1.1 创始背景与早期积累（1971-2000） 该集团的历史可以追溯到1971年。创始人在江苏省泰州市的一个口岸镇创办了集团的前身。创业初期， 企业主要以生产板蓝根、维生素等基础药物为主，不仅面临资金短缺，更受限于当时计划经济体制下的 统购统销模式。 在1980年代至1990年代，创始人敏锐地抓住了中国医疗卫生体制改革的机遇，确立了"质量兴企"的战略 基石。不同于当时许多乡镇企业追求短期利益的做法，该集团在早期就建立了严格的质量内控标准，这 为其后来在"板蓝根大战"等行业洗牌中脱颖而出奠定了基础。集团充分利用长三角（上海、苏州、杭 州）的地理优势，逐步建立了覆盖华东、辐射全国的销售网络。 1.2 爆发式增长与行业霸主地位（2000-2019） 进入21世纪，该集团迎来了黄金发展期。2003年至2010年间 ...

2025年中国带状疱疹疫苗行业洞察报告：免 疫需求扩容 + 政策红利加持背景下，百克生 物率先获批，国产疫苗如何承接市场？ Expanding immunization demand and supportive policy tailwinds, how can local vaccines capture the market opportunity in 2025? 2025年において、免疫需要の拡大と政策面の追い風を背景に、国 産ワクチンはどのように市場機会を取り込めるのか 报告标签：带状疱疹疫苗、减毒活病毒疫苗、重组亚单位疫苗，mRNA病毒疫苗，自复制 RNA疫苗 主笔人：梁坤媛 研究报告 2025/12 报告提供的任何内容（包括但不限于数据、文字、图表、图像等）均系头豹研究院独有的高度机密性 文件（在报告中另行标明出处者除外）。 ，任何人不得以任何方式擅自 复制、再造、传播、出版、引用、改编、汇编本报告内容，若有违反上述约定的行为发生，头豹研究 院保留采取法律措施、追究相关人员责任的权利。头豹研究院开展的所有商业活动均使用"头豹研究院 "或"头豹"的商号、商标，头豹研究院无任何前述名称之外的其他分 ...

Core Viewpoint - The upcoming Spring Festival is expected to disrupt regular lifestyles, leading to an increase in cases of shingles, particularly among the elderly, due to factors such as seasonal changes, fatigue, and decreased immunity [1][2] Group 1: Health Risks During Spring Festival - The number of shingles patients visiting hospitals significantly increases after the Spring Festival, attributed to seasonal transitions and lifestyle changes that lower immunity [1][2] - Shingles, caused by the varicella-zoster virus, affects over 90% of adults, with about one-third experiencing it in their lifetime, and the risk increases with age, particularly for those over 50 [2] - The elderly face compounded health risks, including chronic diseases like hypertension, diabetes, and hyperlipidemia, leading to a scenario termed "three highs and one rash" [2] Group 2: Preventive Measures - Vaccination is emphasized as an effective preventive measure against shingles, especially for individuals aged 50 and above, regardless of previous chickenpox or shingles history [3] - The Chinese Center for Disease Control and Prevention (CDC) advises maintaining warmth and being vigilant about respiratory infections, foodborne illnesses, and other health risks during the festival due to increased population movement [4] Group 3: Specific Health Concerns - The winter-spring season sees a rise in acute respiratory infections, with influenza and respiratory syncytial virus being the main pathogens, necessitating good hygiene practices [4] - Norovirus gastroenteritis, which can spread through contaminated food or close contact, poses a risk during family gatherings, highlighting the need for hand hygiene and safe food handling [6] - Foodborne illnesses are also a concern during the festival due to increased food preparation and gatherings, with recommendations for proper food safety practices [7]

春节期间，慢性病人群对于自己的健康管理难免有些松懈，不规律吃药甚至停药、血糖监测不及时等， 一方面既影响自身的疾病控制和管理，另一方面也为带状疱疹的侵袭带来了"可乘之机"。 以糖尿病为例，北京大学第一医院内分泌科主任医师郭晓蕙表示，糖尿病患者发生带状疱疹的风险比普 通人群增加60%。这两种疾病之间存在危险的"多重影响"。一方面，高血糖状态为水痘-带状疱疹病毒 激活创造了条件；另一方面，糖尿病患者罹患带状疱疹后，可能影响血糖控制，造成糖尿病管理难度增 加。患带状疱疹后的剧烈疼痛会引起血糖升高，研究显示：24%的糖尿病患者患带状疱疹后血糖控制恶 化。这样形成"血糖不稳-更易感染，感染后血糖更难控"的恶性循环，严重降低患者生活质量。 目前，带状疱疹的治疗仍以抗病毒、止痛、营养神经为主。虽然抗病毒药物治疗可以一定程度上缩短皮 疹的持续时间，但是通常患者很难在发疹后的72小时内及时开始治疗，而患者超过72小时就诊发生带状 疱疹后神经痛的概率高达41.38%。 同济大学附属杨浦医院疼痛科主任夏明教授表示，目前带状疱疹的治疗方法有限，主要以抗病毒药物和 对症止痛为主，且最佳治疗窗口期短，因此，主动预防远比发病后治疗更重要。 ...

北京大学人民医院皮肤科主任医师 李厚敏：50岁以上还没有得过带状疱疹，就是要去接种的人群。疫 苗的保护性还是非常好的，目前证据证明，它可以保护到10年以上，大大减少带状疱疹的发生概率。 哪些早期症状提示可能患带状疱疹？ 李厚敏：带状疱疹累及的神经是单侧分布的。当出现单侧的胸部、背部、腰部，或者是单侧的上肢、下 肢，或者单侧的头、面部感觉异常，像针刺感，有点痒、麻木、腰部不适的时候，都要注意可能是带状 疱疹。衣服摩擦或者是体位改变的时候，会诱发这种症状的加重。 出现这些感觉几天后，疼痛部位会先出现潮红斑，进而转为水疱。专家提醒，带状疱疹的救治有明确 的"黄金时间窗口"。出现带状疱疹症状的72小时内是治疗的黄金时间，越积极治疗，转成慢性疼痛的概 率就会越低。 没得过水痘就不会得带状疱疹吗？ 很多人在假期会打破原有作息和饮食规律，尤其容易"报复性熬夜"和"过度疲劳式旅行"。这样会导致人 体免疫力下降，让潜伏在体内的水痘——带状疱疹病毒有可乘之机。 哪些人群更易患带状疱疹？ 北京医院（国家老年医学中心）内分泌科主任医师 郭立新：糖尿病患者罹患带状疱疹的风险比一般的 人高60%。糖尿病患者细胞免疫和体液免疫能力下降，抵 ...

春节假期即将来临。多位医生表示，往年每逢春节后，前往医院就诊的带状疱疹患者数量显著增加，这 与春节期间季节交替、过度劳累和生活不规律导致免疫力下降等因素密切相关。 以糖尿病为例，北京大学第一医院内分泌科主任医师郭晓蕙表示，糖尿病患者发生带状疱疹的风险比普 通人群增加60%。这两种疾病之间存在危险的"多重影响"。一方面，高血糖状态为水痘-带状疱疹病毒 激活创造了条件；另一方面，糖尿病患者罹患带状疱疹后，可能影响血糖控制，造成糖尿病管理难度增 加。患带状疱疹后的剧烈疼痛会引起血糖升高，研究显示：24%的糖尿病患者患带状疱疹后血糖控制恶 化。这样形成"血糖不稳-更易感染，感染后血糖更难控"的恶性循环，严重降低患者生活质量。 目前，带状疱疹的治疗仍以抗病毒、止痛、营养神经为主。虽然抗病毒药物治疗可以一定程度上缩短皮 疹的持续时间，但是通常患者很难在发疹后的72小时内及时开始治疗，而患者超过72小时就诊发生带状 疱疹后神经痛的概率高达41.38%。 同济大学附属杨浦医院疼痛科主任夏明教授表示，目前带状疱疹的治疗方法有限，主要以抗病毒药物和 对症止痛为主，且最佳治疗窗口期短，因此，主动预防远比发病后治疗更重要。接种疫苗是 ...

Core Viewpoint - The recent announcement by Shenzhen Kangtai Biological Products Co., Ltd. regarding the termination of the concerted action agreement between its actual controllers, Du Weimin and Yuan Liping, has reignited concerns over the company's control stability and potential shareholder dilution following their high-profile divorce that split a market value of 23.5 billion yuan [3][5]. Group 1: Shareholder Dynamics - The termination of the concerted action agreement has resulted in Du Weimin's voting rights decreasing from 46.62% to 25.50%, while Yuan Liping now holds 17.07% [5]. - Yuan Liping has committed not to seek control of the company post-termination, aiming to alleviate market concerns regarding control instability [5]. - Since the divorce in 2020, Yuan Liping has reduced her holdings significantly, cashing out nearly 3 billion yuan, raising fears of further dilution of shares following the termination of the agreement [6]. Group 2: Operational Challenges - Kangtai Biological's core business includes the research, production, and sales of human vaccines, with key products such as the 13-valent pneumococcal polysaccharide conjugate vaccine and others [7]. - The company has faced significant operational challenges, including the resignation of a vice president and the termination of a joint venture with AstraZeneca, which was intended to invest approximately 2.76 billion yuan [8][10]. - The decision to terminate the joint venture was influenced by a rapidly changing market environment and increased risks associated with new investments in the vaccine industry [10]. Group 3: Financial Performance - Kangtai Biological's financial outlook is concerning, with a projected net profit for 2025 expected to decline by 63.80% to 75.70%, amounting to between 49 million and 73 million yuan [10]. - The company's performance has been volatile, with net profits peaking at 1.263 billion yuan in 2021, followed by a loss of 133 million yuan in 2022, and a recovery in 2023 and 2024, only to face another significant decline in 2025 [11]. - As of February 11, 2026, the company's stock price has plummeted nearly 90% from 146 yuan per share at the time of the divorce, reflecting a substantial decrease in valuation [11].

春节即将到来，大家各有各的快乐"忙法"：50岁-60岁的中老年人是家中的"顶梁柱"，忙前忙后地打扫 卫生、收拾屋子、准备丰盛的大餐；年轻人忙着聚餐、熬夜打游戏或追剧。专家11日在此间接受记者采 访时提醒，过度劳累、免疫力下降人群容易被带状疱疹"盯上"。 据悉，带状疱疹俗称"蛇缠腰""缠腰龙"，是一种由水痘-带状疱疹病毒引起的感染性皮肤病。50岁以上 为易发人群，年龄越大者越容易患病，病情也更严重。 "尤其对于50岁及以上人群，不论是否曾患过水痘或带状疱疹，都应积极接种带状疱疹疫苗。"同济大学 附属杨浦医院疼痛科主任夏明教授对记者表示，目前带状疱疹的治疗方法有限，主要以抗病毒药物和对 症止痛为主，且最佳治疗窗口期短，因此，主动预防远比发病后治疗更重要。接种疫苗是预防带状疱疹 的有效方式。 这位专家表示，接种疫苗前可就疫苗的保护效果、保护时长、接种禁忌、安全性等信息咨询专业医生， 进行科学接种。此外，预防带状疱疹的方法还包括：提高基础抵抗力，清淡饮食，适度锻炼。 据悉，带状疱疹不是"小病"，其疼痛与后遗神经痛可能长期困扰患者。对于50岁以上，患有糖尿病、高 血压等慢性病，免疫力较低的人群而言，做好主动预防，是远离 ...

Core Viewpoint - Changchun High-tech, a leading company in the growth hormone industry, is experiencing a significant decline in net profit, with a forecasted drop of 91.48% to 94.19% for 2025 compared to the previous year [1] Group 1: Financial Performance - In the third quarter of 2025, Changchun High-tech reported a revenue of 9.807 billion yuan, a decrease of 5.6% year-on-year, and a net profit of 1.165 billion yuan, down 58.23% year-on-year [1] - The peak net profit for Changchun High-tech was 4.532 billion yuan in 2023, but it fell by 43% in 2024, indicating a continuing downward trend into 2025 [1] - The company anticipates a net profit of 150 million to 200 million yuan for 2025, marking a substantial decline from previous years [1] Group 2: Market and Product Dynamics - The sales of growth hormones are influenced by the number of adolescents and newborns, with increased competition also impacting performance [2] - Changchun High-tech's long-acting growth hormone and related products have been included in the new national medical insurance directory, effective January 1, 2026, with a price reduction of approximately 75% [2] - The company has adjusted its sales policies and pricing in response to industry policy changes and market conditions, which has contributed to reduced revenue and net profit [2] Group 3: Subsidiary Performance - Changchun High-tech's subsidiary, Baike Biological, is expected to report a net loss of 220 million to 280 million yuan for 2025, marking its first loss since going public, primarily due to intensified competition and decreased vaccination willingness [3] - The sales revenue of the shingles vaccine from Baike Biological has already seen a decline of 71.54% in 2024, continuing to be negatively affected in 2025 [4] - Factors affecting the shingles vaccine sales include public awareness of the disease, vaccination willingness, and increased market competition, leading to unsold inventory and returns [4]

该公司还维持了今年利润增长7%至9%的指引。部分分析师此前预计的指引约为每股收益增长 6%至8%，新任首席执行官卢克·米尔斯为这一年设定了一个可能被超越的目标，其中抗癌药物 Blenrep有望提振收入。 葛兰素史克预计 2026 年营业额增长 3% 至 5%；核心营业利润增长 7% 至 9%；核心每股收 益增长 7% 至 9%。该公司预计到 2031 年销售额将超过 400 亿英镑。 葛兰素史克(GSK.US) 第四季度利润高于预期，这主要得益于其艾滋病(HIV)药物以及一款现已获批用 于治疗肺部疾病的哮喘药物。财报显示，葛兰素史克四季度营收达 86.2 亿英镑，同比增长 6.3%，超 出预期 1.7 亿英镑；调整后每股收益为 25.5 便士(约合 35 美分)，高于分析师的预期。 该公司经营活动产生的现金流为 89 亿英镑，自由现金流为 40 亿英镑。 在前CEO沃尔姆斯利执掌期间，葛兰素史克拆分了其消费者健康部门 Haleon，并进行了关键收 购以尝试增强其药物研发管线。尽管如此，米尔斯仍需向投资者证明，公司能够实现本十年末及 更长远时期的营收抱负。上个月，葛兰素史克同意以 22 亿美元的交易价格收购总部 ...